In April 1994, the results of a Merck-sponsored study, the Scandinavian Simvastatin Survival Study, were announced. Researchers tested simvastatin, later sold by Merck as Zocor, on 4,444 patients with high cholesterol and heart disease. After five years, the study concluded the patients saw a 35% reduction in their cholesterol, and their chances of dying of a heart attack were reduced by 42%. In 1995, Zocor and Mevacor both made Merck over US$1 billion. Endo was awarded the 2006 Japan Prize, and the Lasker-DeBakey Clinical Medical Research Award in 2008. For his "pioneering research into a new class of molecules" for "lowering cholesterol,"[sentence fragment] COUNT 10
QSN1 Who received the Laser-Debakey Clinical Medical Research Aware? ANS1 Endo QSN2 How much money did Merk make in 1995? ANS2 over US$1 billion QSN3 How many patients received Zocor? ANS3 4,444 QSN4 What study did Merk sponsor in 1994? ANS4 Scandinavian Simvastatin Survival Study QSN5 What did the study reveal after 5 years? ANS5 a 35% reduction in their cholesterol, and their chances of dying of a heart attack were reduced by 42% QSN6 What was the brand name of simvastatin? ANS6 Zocor QSN7 Patients treated with Zocor had their cholesterol reduced by how much? ANS7 35% QSN8 How much did Zocor reduce the chance of dying from a heart attack? ANS8 42% QSN9 How much money did Merck make from sales of Zocor and Mevacor? ANS9 over US$1 billion QSN10 Endo received what award in 2008? ANS10 Lasker-DeBakey Clinical Medical Research Award